BY OUR PLATFORMS
BY THERAPEUTIC AREA
ZeClinics was founded to challenge how preclinical research was performed. We believed preclinical drug discovery and development should be more predictive, so clinical trials would have better chances of success. And we believed preclinical research should be faster and more efficient, so patients would benefit earlier from discoveries. The aims were ambitious, but our reasons were simple: we wanted to bring better drugs to patients in a shorter time.
We knew that zebrafish could provide faster results and better biological translatability than other preclinical models. And we knew our expertise using this amazing tiny fish could provide solutions to those huge challenges. That was the start of this amazing journey.
But the road doesn’t end here. Innovation is at our core and we keep disrupting the drug discovery field by combining zebrafish biology with lab automation and artificial intelligence. Because we want to provide even faster and more reliable preclinical research. And we know how to do it.
ZeClinics is born. Thanks to the support of the Universitat Pompeu Fabra, the company set up its laboratory in the Barcelona Biomedical Research Park, where it began providing services to international clients, attracted by their innovative research model.
ZeClinics is a pioneer in the Barcelona biomedical ecosystem by completing the first round of crowdfunding through the Capital Cell Platform. Revenues from the service activity continue to grow steadily, and the granting of several fellowships and grants allows the company to expand its scientific and commercial team.
ZeClinics is awarded a SME instrument Phase 2 from the H2020 Program worth 1.8 million euros. This grant allows us to implement lab automation processes in our research. It also allows the development of ZeCardio, a platform to analyze cardiovascular parameters in a high-throughput manner. ZeClinics experiences substantial growth in terms of team size and number of ongoing projects. We open a new office to host the commercial and administrative growing team.
The ZeClinics research team moves to IGTP, where the company acquires a larger laboratory space to accommodate its growing scientific team. We also built our own fish facility at the nearby CMCIB. In 2019 the company found its first spin off, ZeCardio Therapeutics, a pharmaceutical company seeking to discover drugs related to cardiovascular diseases. In 2020, ZeCardio Therapeutics managed to raise 800,000 euros despite the COVID-19 pandemic. The company continues its growth in terms of number of developed projects, number of clients and team. Currently, ZeClinics consists of more than 30 people, most of whom are international scientists with PhDs.
The most important asset of the company and a large factor in our success is our team. We have recruited specialist scientists and created a friendly working culture that includes flexible working hours and a profit-sharing scheme for our staff, which has produced an environment of continual growth and innovation.
The investment of time and effort that ZeClinics has put into building a healthy company culture is because we are convinced that this encourages intellectual freedom, an open mind and spirit, and ultimately better innovation.
We are all working together to generate better, safer, and more efficient biomedical research for the benefit of society.
We are proud to be able to count on motivated scientists covering all the different phases of drug discovery from library screening to model generation and validation, safety and efficacy assessment. We are experts in zebrafish biology and the application of the zebrafish model.
We like to highlight that most of our scientists have a PhD. They are flexible, able to work on both basic and applied research projects and have a broad vision of the business of bringing science to clinical practice.
Vincenzo Di Donato
Filippo Del Bene
Elisabet Mateu has a degree in Biotechnology and Biochemistry from the Autonomous University of Barcelona. She did her doctoral thesis at the Center for Genomic Regulation and, later, she completed a full-time MBA at IESE of the University of Navarra. Elisabet spent two years at Janssen, a Johnson & Johnson affiliate, working on drug development for myeloid diseases. Since October 2020, she leads the commercial and marketing teams at ZeClinics. Her more than ten years of experience in basic research, and more than six years in management positions in the area of the pharmaceutical industry are essential for the development of ZeClinics commercial strategy.
Vincenzo Di Donato is an Italian researcher, expert in genetics and molecular biology. After a master's degree in molecular biology at the University of Naples, he obtained his PhD in neuroscience from the Curie Institute in Paris, where he chose the zebrafish as an animal model to study the development of the visual system of vertebrates. In 2017 Vincenzo joined the ZeClinics team in Barcelona as a postdoc, to subsequently fill the position of head of the genetics area by 2019. Since November 2020, he has held the position of scientific director of the company. His expertise in innovative CRISPR/Cas9-based gene editing techniques has crucially contributed to the know-how of the company.
Dr. Javier Terriente is a biochemist with a Ph.D. in developmental genetics. He has more than 20 years of research experience in the Academy and the biotech sector. In 2013, he co-founded ZeClinics. Recently, Javier co-founded ZeCardio Therapeutics (www.zecardiotherapeutics.com). This spinout from ZeClinics focuses in the discovery of therapies to treat cardiovascular diseases. From 2013 to 2020 he was Chief Scientific Officer in ZeClinics. He now plays the same role in ZeCardioTx, while acting as Chief of Drug Discovery in ZeClinics. Per his role in both companies, Javier manages a growing scientific team, has directed several Ph.D. theses, and published multiple research articles, including several articles on the use of zebrafish for drug and target discovery. In addition to these roles, he serves as Vicepresident at Asebio, the Spanish association of biotech companies.
Dr. Davide D'Amico is a medical biotechnologist with a Ph.D. in neuroscience. He has more than 15 years of research and business track records in the Academy and the biotech sector. In 2013, Davide decided to give a spin to his career toward the private sector and he co-founded ZeClinics. Recently, Davide co-founded ZeCardio Therapeutics (www.zecardiotherapeutics.com), a spinout from ZeClinics, focused on the discovery of therapies to treat cardiovascular diseases. From 2013 to 2020 he served as Chief Executive Officer at ZeClinics and since 2020 he moved to the executive direction of ZeCardioTx, as CEO while acting as Chairman of the Board in ZeClinics. Per his past and current roles in both companies, Davide had and has the vision to build sustainable and fast-growing biotech assets with clear potential in scientific and business directions, raising and managing capital and funds, directing investment and departments, and assuring that amazing science is translated into a tangible benefit for society.
With a Ph.D. in Economics and a Master's degree in Finance from the University of Santiago de Compostela and Carlos III of Madrid, respectively, Miguel has +20 years of working experience in the areas of corporate finance, treasury, and capital markets products, having worked in different managerial roles for a number of international institutions such as ING and EBRD (European Bank for Reconstruction & Development). Miguel brings extensive experience in the area of corporate finance to ZeClinics, having been involved in multiple European capital markets transactions at the senior level (M&As, LBOs, debt restructurings, and securitizations).
Ignasi Sahún is a criminologist and clinical psychologist with a Ph.D. in Neurosciences and more than 20 years of experience in Academy. From 2012 to 2017, he designed and led the Phenotyping Unit of the PCB-PRBB Animal Facility Alliance at the Barcelona Science Park (PCB-UB), and he was visiting professor at several universities and research centers (CNIO; UIC; UB; UAB; UPF). In 2013 Ignasi co-founded ZeClinics and during the following years he combined his intense academic activity with the management of the company. From 2017 to 2021 he was the Chief Marketing Officer in ZeClinics, coordinating the development of the marketing department (marketing strategy, social media activity, and communication) and also, managing the HR department. Since January 2021 he has been the Chief Operations Officer of the company.
Dr. Simone Calzolari completed a Master's Degree in Molecular Biotechnology in 2008 at the University of Bologna (Italy). In 2013 he completed his Ph.D. in the Biomedicine Group of DECXS-UPF (Barcelona, Spain). During these years Simone has acquired extensive technical and theoretical experience in the manipulation of embryos of zebrafish in several experimental conditions. In 2013, he co-founded ZeClinics as CCO for several years, leading all commercial activity of ZeClinics. Since January 2021 he has been the Chief Executive Officer of the company.
Florian Engert is currently occupying a Molecular and Cellular Biology Professor position at Harvard University. He received his Ph.D. in 1997 from Max Planck Institute for Neurobiology in Martinsried, Germany. In 2002, he became Neuroscience Assistant Professor at Harvard University, where thereafter in 2006, he became Associate Professor. Florian Engert's laboratory works for establishing the larval zebrafish as a model system for visually induced behaviors and the underlying neuronal activity. Florian Engert was awarded the Janssen-Cilag Award by Young Investigators. He was also awarded McKnight, Klingenstein, and Dana Research Fellowships and he is a member of the Society for Neuroscience.
Filippo Del Bene is currently one of the Principal Researchers at the Institut de la Vision in Paris. He received his PhD in 2005 from the laboratory of Professor Jochen Wittbrodt at the EMBL. He continued his work on the development and function of the visual system as a postdoctoral fellow in the laboratory of Professor Herwig Baier, at the University of California San Francisco. From 2010 to 2019, he directed his independent team at the Institute Curie in Paris. The Del Bene group works to achieve complete understanding of visual neuronal circuit development and function in an intact behaving animal. To address this question, his group uses zebrafish embryos and larvae as a model to understand the molecular control underlying the development of connections between the retina and the visual processing areas of the brain. He focuses the analysis on the retinal ganglion cells and the optic tectum.